Back to top
more

Certara (CERT)

(Real Time Quote from BATS)

$17.11 USD

17.11
18,048

0.00 (0.00%)

Updated May 1, 2024 10:08 AM ET

Zacks Rank:

This is our short term rating system that serves as a timeliness indicator for stocks over the next 1 to 3 months. How good is it? See rankings and related performance below.

Zacks Rank Definition Annualized Return
1Strong Buy24.20%
2Buy18.04%
3Hold9.52%
4Sell5.20%
5Strong Sell2.60%
S&P50011.13%

Zacks Rank Education - Learn about the Zacks Rank

Zacks Rank Home - Zacks Rank resources in one place

Zacks Premium - The only way to fully access the Zacks Rank

3-Hold of 5     3    

Style Scores:

The Style Scores are a complementary set of indicators to use alongside the Zacks Rank. It allows the user to better focus on the stocks that are the best fit for his or her personal trading style.

The scores are based on the trading styles of Value, Growth, and Momentum. There's also a VGM Score ('V' for Value, 'G' for Growth and 'M' for Momentum), which combines the weighted average of the individual style scores into one score.

Value Score A
Growth Score A
Momentum Score A
VGM Score A

Within each Score, stocks are graded into five groups: A, B, C, D and F. As you might remember from your school days, an A, is better than a B; a B is better than a C; a C is better than a D; and a D is better than an F.

As an investor, you want to buy stocks with the highest probability of success. That means you want to buy stocks with a Zacks Rank #1 or #2, Strong Buy or Buy, which also has a Score of an A or a B in your personal trading style.

Zacks Style Scores Education - Learn more about the Zacks Style Scores

C Value C Growth F Momentum D VGM

Industry Rank:

The Zacks Industry Rank assigns a rating to each of the 265 X (Expanded) Industries based on their average Zacks Rank.

An industry with a larger percentage of Zacks Rank #1's and #2's will have a better average Zacks Rank than one with a larger percentage of Zacks Rank #4's and #5's.

The industry with the best average Zacks Rank would be considered the top industry (1 out of 265), which would place it in the top 1% of Zacks Ranked Industries. The industry with the worst average Zacks Rank (265 out of 265) would place in the bottom 1%.

Zacks Rank Education -- Learn more about the Zacks Rank
Zacks Industry Rank Education -- Learn more about the Zacks Industry Rank

Top 29% (73 out of 251)

Industry: Medical - Biomedical and Genetics

Zacks Premium FeatureView All Zacks #1 Ranked Stocks

Better trading starts here.

Zacks News

Puma Biotechnology (PBYI) Soars 14.0%: Is Further Upside Left in the Stock?

by Zacks Equity Research

Puma Biotechnology (PBYI) saw its shares surge in the last session with trading volume being higher than average. The latest trend in earnings estimate revisions may not translate into further price increase in the near term.

Certara, Inc. (CERT) Lags Q4 Earnings Estimates

by Zacks Equity Research

Certara, Inc. (CERT) delivered earnings and revenue surprises of -18.18% and 1.40%, respectively, for the quarter ended December 2023. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Q3 Earnings Meet Estimates

by Zacks Equity Research

Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 0.45%, respectively, for the quarter ended September 2023. Do the numbers hold clues to what lies ahead for the stock?

Are Options Traders Betting on a Big Move in Certara (CERT) Stock?

by Zacks Equity Research

Investors need to pay close attention to Certara (CERT) stock based on the movements in the options market lately.

Avidity Biosciences, Inc. (RNA) Reports Q2 Loss, Tops Revenue Estimates

by Zacks Equity Research

Avidity Biosciences, Inc. (RNA) delivered earnings and revenue surprises of 21.43% and 11.08%, respectively, for the quarter ended June 2023. Do the numbers hold clues to what lies ahead for the stock?

Certara, Inc. (CERT) Matches Q1 Earnings Estimates

by Zacks Equity Research

Certara, Inc. (CERT) delivered earnings and revenue surprises of 0% and 1.14%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Guardant Health (GH) Expected to Beat Earnings Estimates: Should You Buy?

by Zacks Equity Research

Guardant Health (GH) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Repligen (RGEN) Surpasses Q1 Earnings and Revenue Estimates

by Zacks Equity Research

Repligen (RGEN) delivered earnings and revenue surprises of 8.47% and 0.91%, respectively, for the quarter ended March 2023. Do the numbers hold clues to what lies ahead for the stock?

Factors to Note Ahead of Atlassian's (TEAM) Q3 Earnings Release

by Zacks Equity Research

Atlassian's (TEAM) Q3 results are likely to reflect the benefits of increased demand for its solutions amid accelerated digital transformations and cloud adoptions.

DraftKings (DKNG) to Report Q1 Earnings: What's in Store?

by Zacks Equity Research

DraftKings' (DKNG) first-quarter 2023 performance is likely to have benefited from the robust demand for mobile sports betting and expansion efforts in new states.

Certara, Inc. (CERT) Earnings Expected to Grow: What to Know Ahead of Next Week's Release

by Zacks Equity Research

Certara, Inc. (CERT) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

The Zacks Analyst Blog Highlights Shake Shack, Wingstop, AssetMark Financial, Primerica and Certara

by Zacks Equity Research

Shake Shack, Wingstop, AssetMark Financial, Primerica and Certara are included in this Analyst Blog.

Nalak Das headshot

5 Must-Buy High-Flying Mid-Cap Stocks Ahead of Q1 Earnings

by Nalak Das

We have narrowed our search to five stocks that are set to report first-quarter 2023 earnings results. These are: SHAK, WING, AMK, PRI and CERT.

Creative Medical (CELZ) Up 86% on Upbeat Diabetes Study Data

by Zacks Equity Research

Creative Medical Technology (CELZ) reports positive one-year follow-up data from a study showing the efficacy of CELZ-001 in treating type II diabetes without any serious adverse effects.

Moderna (MRNA) Posts 2027 Biz View, Down 3% on Flu Jab Setback

by Zacks Equity Research

Moderna (MRNA) expects $8-$15 billion in product revenues from the respiratory vaccine by 2027. Its first influenza vaccine candidate failed to meet the statistical threshold for early success.

Moderna (MRNA), Merck's Cancer Jab Gets EMA's PRIME Tag

by Zacks Equity Research

The EMA grants PRIME designation to Moderna's (MRNA) personalized cancer vaccine candidate combined with Merck's Keytruda for treating certain types of melanoma.

MorphoSys Up on Finishing Early Enrolment in Myelofibrosis Study

by Zacks Equity Research

As MorphoSys (MOR) completes enrolment before schedule in a late-stage study evaluating therapy in myelofibrosis patients, the top-line data from this study is now expected early.

AstraZeneca's (AZN) Drug Combo Meets Ovarian Cancer Study Goal

by Zacks Equity Research

Interim data from a late-stage study shows that AstraZeneca's (AZN) cancer drugs, Lynparza and Imfinzi improved progression-free survival in certain patients with advanced ovarian cancer.

VBI Vaccines (VBIV) Down 53% on Initiating Restructuring Plans

by Zacks Equity Research

VBI Vaccines (VBIV) will focus on its HBV vaccine product and advancing its HBV immunotherapeutic candidate. It will also reduce the workforce by 30-35% and initiate a 1-for-30 reverse stock split.

Ascendis (ASND) Down on Hypoparathyroidism Drug NDA Deficiencies

by Zacks Equity Research

The FDA identifies deficiencies in Ascendis' (ASND) regulatory filing for TransCon PTH in hypoparathyroidism. This might lead to an extended review timeline of the company's filing.

Biomea (BMEA) Up 99% on Upbeat Data From Type II Diabetes Study

by Zacks Equity Research

Preliminary data from an ongoing mid-stage study shows that treatment with Biomea's (BMEA) lead candidate demonstrated a robust glucose-lowering response in patients with type II diabetes.

GSK's Jemperli Effective Against First-Line Endometrial Cancer

by Zacks Equity Research

A late-stage study data shows that GSK's Jemperli reduced disease progression risk or death by 72% for treating adult patients with dMMR/MSI-H primary advanced or recurrent endometrial cancer.

Jounce (JNCE) Up 21% on Accepting Concentra's Buyout Offer

by Zacks Equity Research

Jounce Therapeutics (JNCE) is set to be acquired by Concentra Biosciences, spurning an all-share merger deal with British biotech firm Redx Pharma.

Iovance (IOVA) Completes Rolling BLA Filing for Melanoma Drug

by Zacks Equity Research

Following the completion of Iovance's (IOVA) regulatory filing for its lead candidate in melanoma indication, the FDA has 60 days to determine the acceptability of the BLA for review.

Axsome (AXSM) Stock Up 17% in Six Months: Here's Why

by Zacks Equity Research

Axsome's (AXSM) shares have surged 17.2% in the past six months, owing to the launch of its first product, Auvelity, in October last year. Also, the addition of Sunosi boosts its top line.